Arcus Biosciences (RCUS) Tops Q1 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. FISV
10. CVS

Go back to Arcus Biosciences (RCUS) Tops Q1 EPS by 6c

Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update

May 9, 2023 4:05 PM EDT

Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers. The third dose-escalation cohort (100mg) of ARC-20 for AB521, a potential best-in-class HIF-2a inhibitor, is enrolling; the dose-expansion stage of ARC-20 and a Phase 2 combination study in clear-cell renal cell carcinoma (ccRCC) patients are expected to begin in the third quarter. Three new drug candidates are expected to advance into the clinic in 2023 and early 2024. With $1.0 billion in cash,... More